Absci Corporation, the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, announced that it has entered into a research collaboration with Merck, known as MSD outside of the United States and Canada, using Absci’s AI-powered Integrated Drug Creation™ Platform.